Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?

ar2722 ARJ Review Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease? Melis Lode lode.melis@ugent.be Elewaut Dirk dirk.elewaut@ugent.be

Department of Rheumatology, Ghent University Hospital, 0K12IB, De Pintelaan 185, 9000 Ghent, Belgium

Arthritis Research & Therapy 1478-6354 2009 11 3 233 http://arthritis-research.com/content/11/3/233 1959163710.1186/ar2722 25 6 2009 2009 BioMed Central Ltd

Abstract

Spondyloarthritides, or SpA, form a cluster of chronic inflammatory diseases with the axial skeleton as the most typical disease localisation, although extra-articular manifestations such as intestinal inflammation may frequently occur during the course of the disease. This review summarises recent progress in our understanding of the immunopathogenesis of SpA with special emphasis on the cellular constituents considered to be responsible for the initiation and/or perpetuation of inflammation. There are several arguments favouring a role for haematopoietic cells in the pathophysiology of spondyloarthritis, including HLA-B27-associated dendritic cell disturbances, HLA-B27 misfolding properties and T helper 17 cells. In addition, recent studies have pointed toward a pivotal role for stromal cells. A major challenge, however, remains to determine how recently identified genetic associations such as interleukin-23 receptor polymorphisms may influence cellular targets in spondyloarthritis.

Progress in spondylarthritis Matthew Brown and Dirk Elewaut

Introduction

Spondyloarthritides, or SpA, are a group of chronic inflammatory diseases that affect about 0.5% of the Western population. The most typical disease localisation is the axial skeleton, more specifically the spine and sacroiliac joints. Additionally, enthesitis or peripheral arthritis of the large joints of the lower limbs frequently occurs. Extra-articular manifestations are also a common feature in SpA. They include anterior uveitis, psoriasis and inflammatory bowel disease (IBD).

SpA refers to a cluster of disorders that were formerly considered separate disease entities. It comprises ankylosing spondylitis (AS), reactive arthritis (ReA), IBD-associated arthritis and some forms of psoriatic arthritis (PsA). This grouping was based on three important considerations: (a) the different disease phenotypes could consecutively manifest in the same patient, (b) overlaps that make it impossible to distinguish between the different disorders are often seen, and (c) different disorders can affect different members of the same family. Apart from the presence of shared environmental factors, this familial aggregation can be explained for the most part by an important hereditary component in the pathogenesis of the disease. First-degree relatives of SpA patients are 40 times more likely than the general population to develop SpA 12.

Features of inflammation in spondyloarthritides

For many years, an intimate relationship between mucosal and joint inflammation has been established (reviewed in 3). Pioneering studies by Mielants and Veys 4 demonstrated that about 60% of SpA patients displayed microscopic signs of inflammation in the colon and/or ileum which were unrelated to clinical gastrointestinal symptoms. This illustrates that SpA is a disorder in which many different types of organs may be involved. Extensive studies have been undertaken to characterise the nature of the inflammatory infiltrates in synovial tissue, entheses as well as extra-articular tissues such as colon and/or ileum. Bone marrow inflammation may also occur during the course of SpA and is even considered by some investigators to be one of the principal and initial events 5. This inflammation can be focal or diffuse. It can be located in both sacral and iliac bones and consists of an accumulation of mononuclear cells. These cells were reported to contain plenty of T lymphocytes that can be CD4⁺as well as CD8⁺6789.

In the overlaying synovium and enthesis, the predominant cells are macrophages that often carry the scavenger receptor CD163 at the cell surface 1011. Intriguingly, in the gut, signs of acute inflammation, characterised by infiltration of polymorphonuclear cells, as well as of chronic inflammation, characterised by a mixed macrophage-lymphocyte infiltrate, can be found, and accordingly, subgroups of gut inflammation related to SpA have been described 412. The macrophages in the gut are also frequently CD163⁺13. Remarkably, even in the absence of histological signs of active inflammation, the frequency of dendritic cells (DCs) and T cells was still found to be increased in ileal mucosa of SpA patients 14. In all of the tissues involved in the SpA phenotype, an extensive neovascularisation is present 15. A striking feature of SpA is that the joint involvement combines features of bone destruction versus bone remodelling, which distinguishes it from other inflammatory rheumatic disorders, notably rheumatoid arthritis (RA) 16. In the remaining part of this review, we will summarise recent progress in our understanding of the immunopathogenesis of SpA, with special emphasis on the cellular constituents considered to be responsible for the initiation and/or perpetuation of inflammation in SpA.

The crucial role for mesenchymal cells in tumour necrosis factor-dependent inflammation

The strongest experimental evidence aimed at defining cellular targets for inflammation in SpA was found in the TNF^ΔAREmouse model, characterised by a 69-base pair deletion of the tumour necrosis factor (TNF) AU-rich elements (AREs) from the mouse genome. This leads to increased steady-state TNF mRNA levels in both haematopoietic and stromal tissues as well as a diminished translational silencing of the TNF message. The animals spontaneously develop an inflammatory disease characterised by Crohn-like ileitis, sacroiliitis, enthesitis and peripheral arthritis, making this model very attractive for studying SpA 17. Several mechanistic studies were undertaken to determine the cellular source providing pathogenic TNF loads as well as the cellular targets of pathogenic TNF.

Although gut and joint inflammation coexist in this model, it appeared that some striking differences do exist in the regulation of Crohn-like ileitis as opposed to peripheral arthritis. Hence, in the absence of mature B and T cells, peripheral arthritis still occurred whereas the intestinal phenotype was almost completely prevented 17, suggesting that intestinal inflammation in this model depends on adaptive immune responses. An additional study revealed that a redundancy in the cellular source of TNF-driving Crohn-like ileitis exists and that both myeloid cells or T lymphocytes are sufficient to provide pathogenic TNF loads 18.

To address which cell types respond to chronic TNF overexposure, bone marrow engraftment experiments were carried out to assess the role of TNF receptor I (TNFRI) in the development of arthritis and IBD in these mice. Transfer of TNF^ΔARETNFRI^-/-bone marrow into wild-type irradiated recipients resulted in an IBD and arthritis phenotype similar to that of TNF^ΔARE-reconstituted wild-type mice. By contrast, when TNF^ΔAREbone marrow was transferred to TNFRI^-/-recipients, no signs of joint inflammation were found, although gut inflammation was present. This suggests that radiation-resistant, tissue stroma-residing cells are required TNF targets for the induction of arthritis. However, for the development of IBD, radiation-sensitive, bone marrow-derived cells are equally important and sufficient targets for pathogenic TNF. These findings clearly indicate the existence of independent, yet redundant, cellular pathways operating downstream of TNF in the pathogenesis of IBD 1819.

Furthermore, activation of mesenchymal cell types from gut and joint appeared prior to the onset of clinically overt disease. A formal proof for the importance of stromal cells was shown recently by Armaka and colleagues 19 using Cre/loxP-mediated TNFRI expression in mesenchymal cells. In the presence of chronic TNF overexposure, signalling through TNFRI in synovial fibroblasts and intestinal myofibroblasts appears to be sufficient to develop combined gut and joint pathologies, a hallmark of SpA. However, it remains to be determined why stromal cells are preferentially activated at certain localisations (for example, enthesis, sacroiliac joints) in SpA rather than at other sites.

Contribution to inflammation of haematopoietic cells

Influence of HLA-B27-associated pathological events

The most important genetic contribution to SpA comes from the HLA-B27 gene, which accounts for approximately 30% of the hereditability 12. In the HLA-B27/human beta 2 microglobulin (Huβ2 m) transgenic rat model, only genetically predisposed strains (Lewis or Fisher rats) with a high copy number of the transgene develop an inflammatory syndrome consisting of spondylitis, sacroiliitis, peripheral arthritis, enterocolitis and psoriasiform skin lesions 202122. Hence, this model can be used to study SpA. The HLA-B27 subtype integrated in the transgene locus is the HLA-B*2705 subtype, which is the common ancestor of the closely related HLA class I allotypes and which has been positively associated with AS in multiple population studies 23. Bone marrow engraftment experiments within this model showed that disease arises as a consequence of a high level of expression of the transgenes in cells of haematopoietic origin 24.

Role of antigen-presenting cells and modulation by HLA-B27

Recently, a hypothesis that implies aberrant formation of immunological synapses was proposed. Additional cell transfer experiments in this model suggested an indispensable and provocative role for HLA-B27, a major histo-compatibility complex (MHC) class I molecule, in modulating CD4⁺T-cell activation 25.

In response to antigen recognition and following adhesion between DCs and T cells, T-cell receptor signalling in cooperation with costimulatory signals mediated by CD28 is critical for initiation and stabilisation of the immunological synapse 26. By contrast, much less is known about the antigen-independent immunological synapse formation, in which a majority of naive CD4⁺T cells exhibit a Ca²⁺response upon contact with DCs in the absence of nominal antigen. It can be expected that costimulatory molecules also play a prominent role in this process 27. Because of the lack of a demonstrable role of MHC class I-restricted CD8⁺T cells, new hypotheses to explain the pathogenicity of HLA-B27 in this model are based on these non-antigen-specific mechanisms as opposed to the classic arthritogenic peptide-based hypotheses.

In those antigen-independent systems, HLA-B27 transgenic DCs (HLA-B27 DCs) showed a dramatically decreased capacity to stimulate T cells. This was not related to altered chemokine production by HLA-B27 DCs but resulted rather from the formation of fewer conjugates between HLA-B27 DCs and T cells. Blocking costimulatory molecules (CD86 on DCs or CD28, CD2 and CD4 on T cells) inhibited a greater proportion of the conjugates formed with control DCs than with HLA-B27 DCs, indicating that HLA-B27 DCs failed to use several T-cell costimulatory molecules involved in synapse formation.

This defective DC function is not secondary to chronic inflammation, because it was also found in premorbid disease-prone rats. In contrast, DC function was not significantly reduced in disease-resistant lines bearing a low copy number of the HLA-B27/Huβ2m transgene or a high copy number of the HLA-B7/Huβ2m transgene 2728.

All together, these findings indicate that defective DC function is a feature particularly related to HLA-B27 and is dependent on the number of copies of the HLA-B27/Huβ2m transgene. Hacquard-Breban and colleagues 2728 proposed that DC function may be a causal mechanism for SpA-like development in this transgenic rat model, perhaps by affecting the induction or maintenance of MHC class II-restricted regulatory T cells. Intriguingly, when DC-induced allogeneic T-cell proliferation was compared among different transgenic lines and crosses with distinct levels of susceptibility to SpA-like disease, stimulatory capacity was inversely correlated with disease susceptibility 29. However, formal proof of this indispensable role of DC dysfunction in SpA pathogenesis still needs to be established in non-transgenic animal models or using adoptive transfer experiments. Evidently, it remains to be determined whether these effects of HLA-B27 on DC function can also be found in humans.

HLA-B27 misfolding and formation of homodimers

Another hypothesis regarding immunopathogenesis relates to the structural capacities of the HLA-B27 molecule, which consists of a trimer of heavy-chain, β2 microglobulin and short peptide. The heavy chain has the tendency to misfold, to accumulate in the endoplasmic reticulum (ER) and to form disulfide-linked homodimers, thereby inducing ER stress.

This accumulation may cause an unfolded protein response (UPR), which induces profound changes in the cellular metabolism, including inhibition of general translation but also transcriptional upregulation of molecular chaperone genes 3031. The contribution of HLA-B27 to spondyloarthritis through misfolding and formation of heavy-chain dimers was recently challenged in the transgenic rat model (as well as in human disease).

The introduction of additional Huβ2m in a disease-prone line resulted in an increased prevalence and severity of arthritis with no effect on diarrhea since this developed in all rats independently of extra Huβ2m. In addition, the introduction of additional Huβ2m in a previously healthy HLA-B27/Huβ2m line (lower transgene copy numbers) induced an even more severe inflammatory syndrome: rats more frequently developed a more severe arthropathy, with more clinical and histopathological similarities to SpA (increased prevalence of axial disease) than in the original model. Moreover, in contrast to disease-prone lines, no evidence of gut inflammation was observed. However, in accordance with the original hypothesis, less HLA-B27 heavy-chain misfolding and dimer formation in combination with lower BiP (binding protein) mRNA (marker of UPR triggering) levels was seen in these rats compared with the same line when no additional Huβ2m was introduced 22. However, care needs to be taken when interpreting these results. Folding properties and UPR triggering of stimulated splenocytes rather than macrophages were analysed in this study. Turner and colleagues 30 pointed out that the biological consequences of HLA-B27 misfolding may differ considerably depending on the cell type. On the one hand, appropriate stimulation of HLA-B27 transgenic macrophages resulted in HLA-B27 upregulation, accumulation of misfolded heavy chains and consequently upregulation of UPR target gene expression. On the other hand, stimulated HLA-B27 transgenic splenocytes revealed little activation of the UPR, which was consistent with minimal HLA-B27 upregulation. Thus, the degree to which additional Huβ2m may reduce the UPR caused by HLA-B27 up-regulation has not been formally established yet. Furthermore, folding properties of HLA-B27 subtypes in humans showed incomplete correspondence to AS, indicated by the fact that one of the four AS-associated HLA-B27 subtypes folded with the same high efficiency as the non-disease-associated subtypes 32. It is not yet clear whether misfolded molecules participate in AS pathogenesis.

HLA-B27 as cell surface ligand for immunomodulatory receptor families

Intriguingly, HLA-B27 in classical (trimer of heavy chain, β2 microglobulin and short peptide) as well as β2m-independent forms may also act as cell surface ligands for immunomodulatory receptor families called the killer cell immunoglobulin (Ig) receptors (KIRs) and the leukocyte Ig-like receptors (LILRs)/Ig-like transcripts (ILTs). KIRs and ILTs modulate activation of other immune receptors 3334. Peripheral blood and synovial fluid leukocytes from patients with spondyloarthritis were shown to express cell surface HLA-B27 heavy-chain dimers 35. In addition, DCs of an HLA-B27⁺individual displayed induction of dimer formation on appropriate stimulation 36. These β2 microglobulin-independent homodimer forms bind a distinct pattern of the KIRs and LILRs compared with classical HLA-B27 complexes 34. Moreover, KIR3DL2-expressing natural killer (NK) and CD4 T cells are expanded in the periphery and synovial fluid of patients with HLA-B27-associated arthritis 37. Interestingly, KIR3DL2 ligation by HLA-B27 homodimers inhibited NK-cell and T-cell clone interferon-gamma production 33. These differences in binding, expression and function of classical HLA complexes on the one hand and β2 microglobulin-independent forms on the other could be involved in the pathogenesis of SpA.

Is spondyloarthritides a T helper 17-mediated disease?

Recently, the role of haematopoietic interleukin-17 (IL-17)-producing T cells, the T helper 17 (Th17) cells, has been raised in a wide variety of autoimmune diseases. These cells typically express the IL-23 receptor (IL-23R) on their membrane (reviewed in 38). In addition, recent studies in IBD 39, psoriasis 40 and most importantly AS 414243 show an important genetic contribution for polymorphisms in the gene that codes for this IL-23R. Thus, the active polymorphisms in the IL-23R gene could indicate an important role for this pathogenic T-cell subset in the development and maintenance of AS. IL-23 by itself does not contribute to early Th17 differentiation. However, it favours the expansion and maintenance of this pathogenic T-cell subset 3844. This suggests that IL-17-producing T cells in SpA patients could abnormally expand under the influence of IL-23. Recently, it was also shown that the expression of CCR6 receptor, with CCL20 as its ligand, selectively identified healthy-control peripheral blood CD4⁺T cells producing IL-17 45.

Intriguingly, Jandus and colleagues 46 found increased numbers of Th17 cells in the peripheral blood of PsA and AS patients compared with RA patients and healthy controls. These cells were more differentiated than their RA and healthy control counterparts. In addition, CCR6⁺cells were more efficient in the production of IL-17 as compared with their CCR6^-counterparts. However, no significant differences were observed in the frequency of Th17 cells among the CCR6⁺population in healthy controls and arthritis patients.

Recently, several groups have investigated the levels of IL-17, IL-23 and CCL20 cytokines in serum and/or synovial fluid from SpA patients. Melis and colleagues 47 reported no significant differences in serum and synovial fluid levels of IL-17 in non-PsA SpA patients with peripheral arthritis versus controls, whereas Wendling and colleagues 48 showed elevated serum levels in an AS patient population and Singh and colleagues 49 showed elevated synovial fluid levels in a cohort of patients with ReA and undifferentiated spondyloarthritis. Importantly, it was shown that CCL20 is capable of attracting effector memory T cells, especially Th17 cells 50. Of interest, we found that synovial fluid CCL20 levels were elevated greatly over the serum levels 47, suggesting a true chemotactic role for CCL20 in attracting this pathogenic T-cell subset to the SpA joint.

Interestingly, an apparent paradoxical relationship between TNF and the IL-23/IL-17 pathway appears to exist. In SpA patients, for example, serum levels of p40 IL-12/23 did not differ significantly from controls and these levels did not change after TNF blockade treatment in contrast to systemic parameters of inflammation 51. These results were confirmed by Melis and colleagues 47 using a more specific p19 IL-23 assay. By contrast, in the TNF^ΔAREmouse model of SpA, an increased frequency of Th17 cells was recently reported. Elevated levels of IL-17-producing CD4 T cells in the terminal ileum of these mice were observed compared with controls 52, although it is unclear whether the disease itself can be attenuated by IL-17 blockade. In addition, the putative relationship between TNF and IL-23 in this model has not been explored yet.

IL-23 seems to be involved in subclinical gut inflammation seen in AS patients as well. Ciccia and colleagues 53 reported that IL-23 was markedly upregulated at the mRNA and protein levels in the terminal ileum in comparison with healthy controls. However, this finding was not associated with a well-defined Th17 response since upregulation of IL-17 and the IL-17-inducing cytokines IL-6 and IL-1β was not seen.

Recently, the contribution of IL-17 was also assessed in proteoglycan-induced arthritis, an SpA model dependent upon immunisation with aggrecan. Although spondylitis – a hallmark of SpA – was not assessed, peripheral disease appeared to occur equally well in the presence or absence of IL-17 54. This indicates that peripheral SpA-associated arthritis is not IL-17-dependent in this model.

In summary, although some data point toward an involvement of haematopoietic Th17 cells in SpA pathogenesis, the current knowledge is too limited to draw firm conclusions. Clearly, more studies are required to evaluate the contribution of Th17 cells in SpA-associated inflammation. Particularly, the biological role of IL-23R polymorphisms on survival and expansion of Th17 cells is still an open question. In addition, the significance of CCL20 to this Th17 system or to the immunopathogenesis of SpA in general is not clear at present.

Conclusions and prospects for the future

Although the cause of SpA is unknown, it is generally accepted that SpA is a multifactorial disease in which a disturbed interplay occurs between the immune system and environmental factors on a predisposing genetic background. Several trails linking the diverse sites of inflammation in SpA have been followed during the past decades. They involve aberrant migration of intestinal lymphocytes or mononuclear cells, particularly macrophages, but neither of these hypotheses has been formally proven. Recent studies have shed new insight into the putative role of an old and intriguing player in SpA pathogenesis, HLA-B27, which displays aberrant folding properties and can form ER and cell surface homodimers. To date, however, it is not clear whether misfolded molecules participate in AS pathogenesis. Other research groups focus on the role of HLA-B27 in affecting DC function in an antigen-independent manner. However, formal proof that DCs are major drivers in SpA pathogenesis is currently lacking. The most convincing experimental breakthrough in defining responsible cellular targets in SpA pathogenesis points toward stromal cells. Hence, TNFRI expression on mesenchymal cells can phenocopy the entire disease spectrum from a TNF-driven model of SpA. Nonetheless, several important questions remain to be addressed. The role of novel identified associations such as the IL-23R – important for Th17 expansion and maintenance – will have to be explored, especially as many of the associated single-nucleotide polymorphisms were associated with a protection against disease.

In conclusion, there is ample evidence that bone marrow as well as stromal cells seem to be involved in SpA pathogenesis. However, the interaction of these cell types remains to be established, especially in human SpA. Furthermore, the potential combined action of HLA-B27 and IL-23R polymorphisms in the pathogenesis of SpA will require a coordinated approach with geneticists as well as immunologists. Hence, all of the identified predisposing genes largely affect adaptive immune responses. With the availability of the various mouse engineering tools that allow these questions to be addressed in a sophisticated manner, it is clear that exciting times for SpA research lie ahead.

Abbreviations

ARE: AU-rich element; AS: ankylosing spondylitis; DC: dendritic cell; ER: endoplasmic reticulum; HLA-B27 DC: HLA-B27 transgenic den-dritic cell; Huβ2m: human beta 2 microglobulin; IBD: inflammatory bowel disease; Ig: immunoglobulin; IL: interleukin; IL-23R: interleukin-23 receptor; ILT: immunoglobulin-like transcript; KIR: killer cell immunoglobulin receptor; LILR: leukocyte immunoglobulin-like receptor; MHC: major histocompatibility complex; NK: natural killer; PsA: psoriatic arthritis; RA: rheumatoid arthritis; ReA: reactive arthritis; SpA: spondyloarthritides; Th17: T helper 17; TNF: tumour necrosis factor; TNFRI: tumour necrosis factor receptor 1; UPR: unfolded protein response.

Competing interests

The authors declare that they have no competing interests.

Note

This review is part of a series on Progress in spondylarthritis edited by Matthew Brown and Dirk Elewaut.

Other articles in this series can be found at http://arthritis-research.com/series/spondylarthritis

Acknowledgements

This work was supported by grants from the Fund for Scientific Research Flanders and by the research council of Ghent University.

Genetics of spondyloarthritis Breban M Best Pract Res Clin Rheumatol 2006 20 593 599 10.1016/j.berh.2006.03.002 16777584 Update on spondyloarthropathies Khan MA Ann Intern Med 2002 136 896 907 12069564 Joint expedition: linking gut inflammation to arthritis Jacques P Elewaut D Mucosal Immunol 2008 1 364 371 10.1038/mi.2008.24 19079200 Inflammation of the ileum in patients with B27-positive reactive arthritis Mielants H Veys EM Lancet 1984 1 288 10.1016/S0140-6736(84)90163-6 6143031 Histopathologic evidence that sacroiliitis in ankylosing spondylitis is not merely enthesitis Francois RJ Gardner DL Degrave EJ Bywaters EG Arthritis Rheum 2000 43 2011 2024 10.1002/1529-0131(200009)43:9<2011::AID-ANR12>3.0.CO;2-Y 11014351 Immunohistologic analysis of zygapophyseal joints in patients with ankylosing spondylitis Appel H Kuhne M Spiekermann S Ebhardt H Grozdanovic Z Kohler D Dreimann M Hempfing A Rudwaleit M Stein H Metz-Stavenhagen P Sieper J Loddenkemper C Arthritis Rheum 2006 54 2845 2851 10.1002/art.22060 16947385 Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow Appel H Kuhne M Spiekermann S Kohler D Zacher J Stein H Sieper J Loddenkemper C Arthritis Rheum 2006 54 1805 1813 10.1002/art.21907 16736521 Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis Appel H Loddenkemper C Grozdanovic Z Ebhardt H Dreimann M Hempfing A Stein H Metz-Stavenhagen P Rudwaleit M Sieper J Arthritis Res Ther 2006 8 R143 1779434 16925803 10.1186/ar2035 Immunohistological study of entheses in spondyloarthropathies: comparison in rheumatoid arthritis and osteoarthritis Laloux L Voisin MC Allain J Martin N Kerboull L Chevalier X Claudepierre P Ann Rheum Dis 2001 60 316 321 1753596 11247858 10.1136/ard.60.4.316 Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis Baeten D Moller HJ Delanghe J Veys EM Moestrup SK De Keyser F Arthritis Rheum 2004 50 1611 1623 10.1002/art.20174 15146432 Histological assessment of the early enthesitis lesion in spondyloarthropathy McGonagle D Marzo-Ortega H O'Connor P Gibbon W Hawkey P Henshaw K Emery P Ann Rheum Dis 2002 61 534 537 1754106 12006328 10.1136/ard.61.6.534 Histopathology of intestinal inflammation related to reactive arthritis Cuvelier C Barbatis C Mielants H De Vos M Roels H Veys E Gut 1987 28 394 401 1432823 3495471 10.1136/gut.28.4.394 Colon mucosa of patients both with spondyloarthritis and Crohn's disease is enriched with macrophages expressing the scavenger receptor CD163 Demetter P De Vos M Van Huysse JA Baeten D Ferdinande L Peeters H Mielants H Veys EM De Keyser F Cuvelier CA Ann Rheum Dis 2005 64 321 324 1755335 15166002 10.1136/ard.2003.018382 Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis Demetter P Van Huysse JA De Keyser F Van Damme N Verbruggen G Mielants H De Vos M Veys EM Cuvelier CA J Pathol 2002 198 517 522 10.1002/path.1235 12434422 Mechanisms of disease: angiogenesis in inflammatory diseases Szekanecz Z Koch AE Nat Clin Pract Rheumatol 2007 3 635 643 10.1038/ncprheum0647 17968334 Joint remodelling in inflammatory disease Schett G Ann Rheum Dis 2007 66 Suppl 3 iii42 44 10.1136/ard.2007.078972 17934094 Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies Kontoyiannis D Pasparakis M Pizarro TT Cominelli F Kollias G Immunity 1999 10 387 398 10.1016/S1074-7613(00)80038-2 10204494 Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease Kontoyiannis D Boulougouris G Manoloukos M Armaka M Apostolaki M Pizarro T Kotlyarov A Forster I Flavell R Gaestel M Tsichlis P Cominelli F Kollias G J Exp Med 2002 196 1563 1574 2196068 12486099 10.1084/jem.20020281 Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases Armaka M Apostolaki M Jacques P Kontoyiannis DL Elewaut D Kollias G J Exp Med 2008 205 331 337 2271010 18250193 10.1084/jem.20070906 Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human beta 2 m: an animal model of HLA-B27-associated human disorders Hammer RE Maika SD Richardson JA Tang JP Taurog JD Cell 1990 63 1099 1112 10.1016/0092-8674(90)90512-D 2257626 Susceptibility to inflammatory disease in HLA-B27 transgenic rat lines correlates with the level of B27 expression Taurog JD Maika SD Simmons WA Breban M Hammer RE J Immunol 1993 150 4168 4178 8473755 Additional human beta2-microglobulin curbs HLA-B27 misfolding and promotes arthritis and spondylitis without colitis in male HLA-B27-transgenic rats Tran TM Dorris ML Satumtira N Richardson JA Hammer RE Shang J Taurog JD Arthritis Rheum 2006 54 1317 1327 10.1002/art.21740 16575857 Peptides: the cornerstone of HLA-B27 biology and pathogenetic role in spondyloarthritis Marcilla M Lopez de Castro JA Tissue Antigens 2008 71 495 506 10.1111/j.1399-0039.2008.01051.x 18489433 Transfer of the inflammatory disease of HLA-B27 transgenic rats by bone marrow engraftment Breban M Hammer RE Richardson JA Taurog JD J Exp Med 1993 178 1607 1616 2191228 8228809 10.1084/jem.178.5.1607 T cells, but not thymic exposure to HLA-B27, are required for the inflammatory disease of HLA-B27 transgenic rats Breban M Fernandez-Sueiro JL Richardson JA Hadavand RR Maika SD Hammer RE Taurog JD J Immunol 1996 156 794 803 8543835 Regulation of T-cell activation by the cytoskeleton Billadeau DD Nolz JC Gomez TS Nat Rev Immunol 2007 7 131 143 10.1038/nri2021 17259969 Alteration of antigen-independent immunologic synapse formation between dendritic cells from HLA-B27-transgenic rats and CD4+ T cells: selective impairment of costimulatory molecule engagement by mature HLA-B27 Hacquard-Bouder C Chimenti MS Giquel B Donnadieu E Fert I Schmitt A Andre C Breban M Arthritis Rheum 2007 56 1478 1489 10.1002/art.22572 17469106 Defective costimulatory function is a striking feature of antigen-presenting cells in an HLA-B27-transgenic rat model of spondylarthropathy Hacquard-Bouder C Falgarone G Bosquet A Smaoui F Monnet D Ittah M Breban M Arthritis Rheum 2004 50 1624 1635 10.1002/art.20211 15146433 Correlation between dendritic cell functional defect and spondylarthritis phenotypes in HLA-B27/HUMAN beta(2)-microglobulin-transgenic rat lines Fert I Glatigny S Poulain C Satumtira N Dorris ML Taurog JD Breban M Arthritis Rheum 2008 58 3425 3429 10.1002/art.24023 18975325 HLA-B27 up-regulation causes accumulation of misfolded heavy chains and correlates with the magnitude of the unfolded protein response in transgenic rats: implications for the pathogenesis of spondylarthritis-like disease Turner MJ Delay ML Bai S Klenk E Colbert RA Arthritis Rheum 2007 56 215 223 10.1002/art.22295 17195225 HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response Turner MJ Sowders DP DeLay ML Mohapatra R Bai S Smith JA Brandewie JR Taurog JD Colbert RA J Immunol 2005 175 2438 2448 16081815 Folding of HLA-B27 subtypes is determined by the global effect of polymorphic residues and shows incomplete correspondence to ankylosing spondylitis Galocha B de Castro JA Arthritis Rheum 2008 58 401 412 10.1002/art.23164 18240209 Interaction of HLA-B27 homodimers with KIR3DL1 and KIR3DL2, unlike HLA-B27 heterotrimers, is independent of the sequence of bound peptide Kollnberger S Chan A Sun MY Chen LY Wright C di Gleria K McMichael A Bowness P Eur J Immunol 2007 37 1313 1322 10.1002/eji.200635997 17407096 Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures Allen RL Raine T Haude A Trowsdale J Wilson MJ J Immunol 2001 167 5543 5547 11698424 Cell-surface expression and immune receptor recognition of HLA-B27 homodimers Kollnberger S Bird L Sun MY Retiere C Braud VM McMichael A Bowness P Arthritis Rheum 2002 46 2972 2982 10.1002/art.10605 12428240 Induction of HLA-B27 heavy chain homodimer formation after activation in dendritic cells Santos SG Lynch S Campbell EC Antoniou AN Powis SJ Arthritis Res Ther 2008 10 R100 2575614 18759962 10.1186/ar2492 Expansion and enhanced survival of natural killer cells expressing the killer immunoglobulin-like receptor KIR3DL2 in spondylarthritis Chan AT Kollnberger SD Wedderburn LR Bowness P Arthritis Rheum 2005 52 3586 3595 10.1002/art.21395 16255049 IL-17 family cytokines and the expanding diversity of effector T cell lineages Weaver CT Hatton RD Mangan PR Harrington LE Annu Rev Immunol 2007 25 821 852 10.1146/annurev.immunol.25.022106.141557 17201677 A genome-wide association study identifies IL23R as an inflammatory bowel disease gene Duerr RH Taylor KD Brant SR Rioux JD Silverberg MS Daly MJ Steinhart AH Abraham C Regueiro M Griffiths A Dassopoulos T Bitton A Yang H Targan S Datta LW Kistner EO Schumm LP Lee AT Gregersen PK Barmada MM Rotter JI Nicolae DL Cho JH Science 2006 314 1461 1463 10.1126/science.1135245 17068223 A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes Cargill M Schrodi SJ Chang M Garcia VE Brandon R Callis KP Matsunami N Ardlie KG Civello D Catanese JJ Leong DU Panko JM McAllister LB Hansen CB Papenfuss J Prescott SM White TJ Leppert MF Krueger GG Begovich AB Am J Hum Genet 2007 80 273 290 1785338 17236132 10.1086/511051 Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants Wellcome Trust Case Control Consortium; Australo-Anglo-American Spondylitis Consortium (TASC) Burton PR Clayton DG Cardon LR Craddock N Deloukas P Duncanson A Kwiatkowski DP McCarthy MI Ouwehand WH Samani NJ Todd JA Donnelly P Barrett JC Davison D Easton D Evans DM Leung HT Marchini JL Morris AP Spencer CC Tobin MD Attwood AP Boorman JP Cant B Everson U Hussey JM Jolley JD Knight AS Koch K Meech E Nat Genet 2007 39 1329 1337 2680141 17952073 10.1038/ng.2007.17 Association of interleukin-23 receptor variants with ankylosing spondylitis Rahman P Inman RD Gladman DD Reeve JP Peddle L Maksymowych WP Arthritis Rheum 2008 58 1020 1025 10.1002/art.23389 18383363 The IL23R Arg381Gln non-synonymous polymorphism confers susceptibility to ankylosing spondylitis Rueda B Orozco G Raya E Fernandez-Sueiro JL Mulero J Blanco FJ Vilches C Gonzalez-Gay MA Martin J Ann Rheum Dis 2008 67 1451 1454 10.1136/ard.2007.080283 18199597 The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells <it>in vivo</it> McGeachy MJ Chen Y Tato CM Laurence A Joyce-Shaikh B Blumenschein WM McClanahan TK O'Shea JJ Cua DJ Nat Immunol 2009 10 314 324 10.1038/ni.1698 19182808 Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells Acosta-Rodriguez EV Rivino L Geginat J Jarrossay D Gattorno M Lanzavecchia A Sallusto F Napolitani G Nat Immunol 2007 8 639 646 10.1038/ni1467 17486092 Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides Jandus C Bioley G Rivals JP Dudler J Speiser D Romero P Arthritis Rheum 2008 58 2307 2317 10.1002/art.23655 18668556 Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis Melis L Vandooren B Kruithof E Jacques P De Vos M Mielants H Verbruggen G De Keyser F Elewaut D Ann Rheum Dis 2009 19196728 Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis Wendling D Cedoz JP Racadot E Dumoulin G Joint Bone Spine 2007 74 304 305 10.1016/j.jbspin.2006.11.005 17369068 Th1/Th17 cytokine profiles in patients with reactive arthritis/undifferentiated spondyloarthropathy Singh R Aggarwal A Misra R J Rheumatol 2007 34 2285 2290 17937463 Regulation of CCR6 chemokine receptor expression and responsiveness to macrophage inflammatory protein-3alpha/CCL20 in human B cells Krzysiek R Lefevre EA Bernard J Foussat A Galanaud P Louache F Richard Y Blood 2000 96 2338 2345 11001880 Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients Wendling D Cedoz JP Racadot E Clin Rheumatol 2009 28 187 190 10.1007/s10067-008-1011-0 18827961 Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease Apostolaki M Manoloukos M Roulis M Wurbel MA Muller W Papadakis KA Kontoyiannis DL Malissen B Kollias G Gastroenterology 2008 134 2025 2035 10.1053/j.gastro.2008.02.085 18439426 Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis Ciccia F Bombardieri M Principato A Giardina A Tripodo C Porcasi R Peralta S Franco V Giardina E Craxi A Pitzalis C Triolo G Arthritis Rheum 2009 60 955 965 10.1002/art.24389 19333939 Development of proteoglycan-induced arthritis is independent of IL-17 Doodes PD Cao Y Hamel KM Wang Y Farkas B Iwakura Y Finnegan A J Immunol 2008 181 329 337 18566398